Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2021

Feb 11, 2022

SELL
$21.47 - $32.08 $1.72 Million - $2.57 Million
-80,185 Closed
0 $0
Q3 2021

Nov 09, 2021

SELL
$23.37 - $32.13 $2.38 Million - $3.27 Million
-101,901 Reduced 55.96%
80,185 $2.47 Million
Q2 2021

Aug 11, 2021

BUY
$18.78 - $25.15 $363,768 - $487,155
19,370 Added 11.9%
182,086 $4.47 Million
Q2 2020

Aug 06, 2020

BUY
$13.31 - $19.41 $656,409 - $957,242
49,317 Added 43.49%
162,716 $3.16 Million
Q1 2020

May 15, 2020

BUY
$13.06 - $21.24 $751,132 - $1.22 Million
57,514 Added 102.91%
113,399 $1.64 Million
Q4 2019

Feb 13, 2020

BUY
$17.29 - $21.74 $966,251 - $1.21 Million
55,885 New
55,885 $1.14 Million

Others Institutions Holding ALKS

About Alkermes plc.


  • Ticker ALKS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 164,254,000
  • Market Cap $3.96B
  • Description
  • Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ...
More about ALKS
Track This Portfolio

Track Platinum Investment Management LTD Portfolio

Follow Platinum Investment Management LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Platinum Investment Management LTD, based on Form 13F filings with the SEC.

News

Stay updated on Platinum Investment Management LTD with notifications on news.